Article
Podoplanin: An emerging cancer biomarker and therapeutic target
Cancer Science
(2018)
Abstract
Podoplanin (PDPN) is a transmembrane receptor glycoprotein that is upregulated on transformed cells, cancer associated fibroblasts and inflammatory macrophages that contribute to cancer progression. In particular, PDPN increases tumor cell clonal capacity, epithelial mesenchymal transition, migration, invasion, metastasis and inflammation. Antibodies, CAR-T cells, biologics and synthetic compounds that target PDPN can inhibit cancer progression and septic inflammation in preclinical models. This review describes recent advances in how PDPN may be used as a biomarker and therapeutic target for many types of cancer, including glioma, squamous cell carcinoma, mesothelioma and melanoma.
Keywords
- c-type lectin-like receptor 2,
- cancer,
- chemotherapy,
- podoplanin
Disciplines
Publication Date
May 1, 2018
DOI
10.1111/cas.13580
Citation Information
Harini Krishnan, Julie Rayes, Tomoyuki Miyashita, Genichiro Ishii, et al.. "Podoplanin: An emerging cancer biomarker and therapeutic target" Cancer Science Vol. 109 Iss. 5 (2018) p. 1292 - 1299 ISSN: 1349-7006 Available at: http://works.bepress.com/gary-s-goldberg/35/